ME02342B - Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom - Google Patents

Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom

Info

Publication number
ME02342B
ME02342B MEP-2016-22A MEP2216A ME02342B ME 02342 B ME02342 B ME 02342B ME P2216 A MEP2216 A ME P2216A ME 02342 B ME02342 B ME 02342B
Authority
ME
Montenegro
Prior art keywords
metered dose
dose inhalers
pharmaceutical solution
solution formulations
pressurised metered
Prior art date
Application number
MEP-2016-22A
Other languages
English (en)
Inventor
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of ME02342B publication Critical patent/ME02342B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-2016-22A 2006-04-21 2007-04-19 Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom ME02342B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
EP07724357.4A EP2010190B1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (1)

Publication Number Publication Date
ME02342B true ME02342B (me) 2016-06-20

Family

ID=38230023

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-22A ME02342B (me) 2006-04-21 2007-04-19 Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom

Country Status (21)

Country Link
US (4) US20060257324A1 (me)
EP (1) EP2010190B1 (me)
JP (1) JP5289306B2 (me)
KR (1) KR101311662B1 (me)
CN (4) CN106074359A (me)
AU (1) AU2007241336C1 (me)
BR (1) BRPI0709510A2 (me)
CA (1) CA2649556C (me)
CY (1) CY1114215T1 (me)
DK (1) DK2010190T3 (me)
EA (1) EA016262B1 (me)
ES (1) ES2424753T3 (me)
HR (1) HRP20130835T1 (me)
ME (1) ME02342B (me)
MX (1) MX2008013460A (me)
PL (1) PL2010190T3 (me)
PT (1) PT2010190E (me)
RS (1) RS52940B (me)
SI (1) SI2010190T1 (me)
WO (1) WO2007121913A2 (me)
ZA (1) ZA200808965B (me)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
SK286394B6 (sk) * 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
KR20070010159A (ko) * 2004-05-13 2007-01-22 키에시 파르마슈티시 엣스. 피. 에이. 화학안정성이 향상된 약제 에어로졸 제제 생성물
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CN103462943A (zh) * 2005-07-15 2013-12-25 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010138158A1 (en) * 2009-05-15 2010-12-02 Map Pharmaceuticals, Inc. Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
KR101795348B1 (ko) * 2009-12-23 2017-12-01 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
EP2515853B1 (en) * 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
PT2515855E (pt) * 2009-12-23 2014-06-11 Chiesi Farma Spa Terapêutica de combinação para dpoc
ES2527604T3 (es) * 2010-02-16 2015-01-27 Teva Branded Pharmaceutical Products R & D, Inc. Una composición farmacéutica inhalable
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
CN102266560A (zh) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 一种用于治疗气喘的药物组合物
NZ605920A (en) * 2010-07-16 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
AU2014375301B2 (en) 2013-12-30 2020-03-26 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition
CA3007050C (en) * 2015-12-04 2020-12-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition comprising a formoterol compound
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6781832B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
EP3922240B1 (en) * 2016-09-19 2023-06-21 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
AU2019282562A1 (en) 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
US11844793B2 (en) 2020-09-29 2023-12-19 Aerorx Therapeutics Llc Liquid formulations of indacaterol
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
NZ246050A (en) * 1991-12-18 1995-12-21 Astra Ab Formerly Aktiebolaget Medicament containing formoterol and budesonide for treatment of respiratory disorders
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
EP1248597B1 (en) 1999-12-24 2005-03-30 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US20030178022A1 (en) 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
MEP30108A (en) * 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
EP2275479A1 (en) * 2003-08-11 2011-01-19 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
AU2007241336C1 (en) 2023-06-29
DK2010190T3 (da) 2013-08-26
AU2007241336A1 (en) 2007-11-01
US20060257324A1 (en) 2006-11-16
US20170065518A1 (en) 2017-03-09
AU2007241336B2 (en) 2012-12-06
RS52940B (en) 2014-02-28
CA2649556C (en) 2014-04-15
EP2010190B1 (en) 2013-06-12
US11213485B2 (en) 2022-01-04
HRP20130835T1 (hr) 2013-10-25
PL2010190T3 (pl) 2013-11-29
SI2010190T1 (sl) 2013-10-30
US20090130026A1 (en) 2009-05-21
EA016262B1 (ru) 2012-03-30
CN102908308A (zh) 2013-02-06
EA200802012A1 (ru) 2009-04-28
CN106074359A (zh) 2016-11-09
MX2008013460A (es) 2008-10-29
US10525006B2 (en) 2020-01-07
JP2009534333A (ja) 2009-09-24
CY1114215T1 (el) 2016-08-31
PT2010190E (pt) 2013-08-26
KR101311662B1 (ko) 2013-09-25
US20200085729A1 (en) 2020-03-19
WO2007121913A3 (en) 2008-03-06
CN105963249A (zh) 2016-09-28
ES2424753T3 (es) 2013-10-08
CN101389341A (zh) 2009-03-18
CA2649556A1 (en) 2007-11-01
JP5289306B2 (ja) 2013-09-11
EP2010190A2 (en) 2009-01-07
ZA200808965B (en) 2009-12-30
BRPI0709510A2 (pt) 2011-07-19
KR20080110985A (ko) 2008-12-22
WO2007121913A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
ZA200808965B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
ZA200709345B (en) Dose counter for metered dose inhalers
HK1145153A1 (en) Metered dose inhaler
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
GB2441053B (en) Drug capsules for dry powder inhalers
GB0614621D0 (en) Metered dose dispensers
EP1888155A4 (en) DOSE COUNTER FOR INHALER
PL2058020T3 (pl) Urządzenie do podawania leków
IL193727A0 (en) Dosage forms for administering combinations of drugs
GB0703507D0 (en) Solid pharmaceutical dose
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
ZA200707513B (en) Dispenser for delivering medicament
EP3388097C0 (en) ADMINISTRATION DEVICE HAVING A UNIT FOR DISPLAYING DOSE VARIATIONS
EP2023900A4 (en) DRUG DELIVERY SYSTEM WITH CONTROLLED DOSES
ZA200909196B (en) Metered dose inhaler actuator
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
ZA200908962B (en) A liquid formulation for administering nicotine
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
EP2012705A4 (en) PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC ACTIVE INJECTION
ZA201101206B (en) Metered dose inhaler
HK1116337A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
HK1103280A1 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ZA200606577B (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers